Table 1.
Predictive value of an end-of-therapy 18F-FDG PET scan for relapse in NHL
| Series | Year | Rituximab (n) | Total no. of cases | No. of HL cases | Relapsed | PET Positive | PET Negative | ||
|---|---|---|---|---|---|---|---|---|---|
| Total | Relapsed n (%) | Total | Relapsed n (%) | ||||||
| De Wit et al18 | 1997 | No | 34 | 17 | 8 | 17 | 8 (47) | 17 | 0 |
| Jerusalem et al 19 | 1999 | No | 54 | 19 | 14 | 6 | 6 (100) | 48 | 8 (17) |
| Zinzani et al 20 | 1999 | No | 44 | 13 | 14 | 13 | 13 (100) | 31 | 1 (3) |
| Mikhaeel et al 21 | 2000 | No | 33 | 0 | 11 | 6 | 6 (100) | 27 | 5 (19) |
| Spaepen et al 22 | 2001 | No | 93 | 0 | 37 | 26 | 26 (100) | 67 | 11 (16) |
| Kostakoglu et al 24 | 2002 | No | 23 | 10 | 11 | 6 | 5 (83) | 17 | 6 (35) |
| Mikosch et al 25 | 2003 | No | 62 | 0 | 27 | 29 | 22 (76) | 33 | 5 (15) |
| Zinzani et al 26 | 2004 | No | 75 | 10 | 14 | 16 | 14 (88) | 59 | 0 |
| Kumar et al 23 | 2004 | No | 18 | 0 | 7 | 6 | 6 (100) | 12 | 1 (8) |
| Reinhardt et al 27 | 2005 | No | 101 | 34 | 28 | 24 | 20 (83) | 77 | 8 (10) |
| Juweid et al 28 | 2005 | Yes (29) | 54 | 0 | 20 | 19 | 13 (68) | 35 | 7 (20) |
| Han et al 29 | 2008 | Yes | 48 | 0 | 7 | 9 | 1 (11) | 39 | 6 (15) |
| Total | 639 | 127 | 198 | 177 | 140 (79) | 462 | 58(13) | ||
Abbreviations: 18F-FDG PET: 18Flourine-Flourodeoxyglucose Positron Emission Tomography, NHL: Non-Hodgkin Lymphoma, HL: Hodgkin Lymphoma.